Pfizer and Moderna vaccines could offer protection for years, study finds
Based on those findings, researchers suggested that immunity might last years, possibly a lifetime, in people who were infected and later vaccinated
The vaccines made by Pfizer-BioNTech and Moderna set off a persistent immune reaction in the body that may protect against the coronavirus for years, scientists reported on Monday.
The findings add to growing evidence that most people immunised with the mRNA vaccines may not need boosters, so long as the virus and its variants do not evolve much beyond their current forms which is not guaranteed, reports the New York Times.
People who recovered from Covid-19 before being vaccinated may not need boosters even if the virus does make a significant transformation.
Keep updated, follow The Business Standard's Google news channel
"It's a good sign for how durable our immunity is from this vaccine," said Ali Ellebedy, an immunologist at Washington University in St. Louis who led the study, which was published in the journal Nature.
The study did not consider the vaccine made by Johnson & Johnson, but Dr Ellebedy said he expected the immune response to be less durable than that produced by mRNA vaccines.
Dr Ellebedy and his colleagues reported last month that in people who had survived Covid-19, immune cells that recognize the virus remained in the bone marrow for at least eight months after infection. A study by another team indicated that so-called memory B cells continue to mature and strengthen for at least a year after infection.
Based on those findings, researchers suggested that immunity might last years, possibly a lifetime, in people who were infected and later vaccinated. But it was unclear whether vaccination alone might have a similarly long-lasting effect.
After an infection or a vaccination, a specialized structure called the germinal center forms in lymph nodes. This structure is an elite school of sorts for B cells.
The broader the range and the longer these cells have to practice, the more likely they are to be able to thwart variants of the virus that may emerge.
After infection with the coronavirus, the germinal center forms in the lungs. But after vaccination, the cells' education takes place in lymph nodes in the armpits, within reach of researchers.
Dr Ellebedy's team found that 15 weeks after the first dose of vaccine, the germinal center was still highly active in all 14 of the participants, and that the number of memory cells that recognized the coronavirus had not declined.
"The fact that the reactions continued for almost four months after vaccination — that's a very, very good sign," Dr Ellebedy said. Germinal centers typically peak one to two weeks after immunization, and then wane.
"Usually by four to six weeks, there's not much left," said Deepta Bhattacharya, an immunologist at the University of Arizona. But germinal centers stimulated by the mRNA vaccines are "still going, months into it, and not a lot of decline in most people."
Dr Bhattacharya noted that most of what scientists know about the persistence of germinal centers is based on animal research. The new study is the first to show what happens in people after vaccination.
The results suggest that a vast majority of vaccinated people will be protected over the long term — at least, against the existing variants. But older adults, people with weak immune systems and those who take drugs that suppress immunity may need boosters; people who survived Covid-19 and were later immunized may never need them at all.
Exactly how long the protection from mRNA vaccines will last is hard to predict. In the absence of variants that sidestep immunity, in theory immunity could last a lifetime, experts said. But the virus is clearly evolving.
